Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data
British Journal of Pharmacology · 09.07.2026
DOI: 10.1111/bph.70592 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, online erschienen am 09.07.2026. Verfasst von Xuerui Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Health Care, Xi'an Children's Hospital, Xi'an, China. Die Arbeit nennt 61 Literaturangaben. Gefördert von: Xi'an Children's Hospital.
Abstract (Originalsprache)
Artificial intelligence (AI) is evolving from a predictive tool into a foundational computational infrastructure for mechanism‐driven pharmacology, fundamentally reshaping drug discovery. This review examines how this transformation addresses persistent challenges in target validation, including data biases and the need for model interpretability, by integrating network pharmacology with advanced deep learning architectures. Specifically, graph neural networks decipher the complex topology of biological systems and transformer models facilitate the fusion of multimodal data, from genomics to real‐world clinical records. Coupled with physics‐informed neural networks, this integrated framework operates as a predictive computational microscope. It enables comprehensive in silico simulations that span multiple biological scales, encompassing atomic‐level molecular interactions and longitudinal patient trajectories. We demonstrate that this AI‐driven paradigm is essential for advancing precision medicine, as it systematically translates vast and heterogeneous datasets into testable mechanistic hypotheses. Consequently, this approach accelerates the development of safer, more effective and patient‐specific therapies, by de‐risking target validation and elucidating novel therapeutic mechanisms. It directly addresses some of the most pressing inefficiencies in contemporary drug discovery and development, offering a pathway towards more rational and efficient therapeutic innovation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Child Health Care, Xi'an Children's Hospital, Xi'an, China.
- School of Computer Science, Northwestern Polytechnical University, Xi'an, China.
- Pediatric Immunology and Rheumatology Department, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection…
- Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Xuerui Song
Förderung
- Xi'an Children's Hospital
Zitieren
APA
Song, X., Chen, Z., An, Y., & Zhang, J. (2026). Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data. British Journal of Pharmacology. https://doi.org/10.1111/bph.70592
Vancouver
Song X, Chen Z, An Y, Zhang J. Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data. British Journal of Pharmacology. 2026. doi:10.1111/bph.70592
BibTeX
@article{Song2026,
author = {Song, Xuerui and Chen, Zhi and An, Yunfei and Zhang, Jie},
title = {Artificial intelligence (AI) as a catalyst for mechanistic target discovery: Integrating systems pharmacology and multimodal data},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70592}
}
EUVIMED